Evaluating new biomarkers for chronic Hepatitis B infection management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on chronic Hepatitis B virus (HBV) infection, which affects millions globally and can lead to severe liver diseases. It aims to evaluate the predictive role of new biomarkers, specifically HBV core-related antigen (HBcrAg) and HBV RNA, in managing the disease and predicting clinical outcomes. The study will involve patients diagnosed with chronic HBV infection who are receiving care at Henri Mondor-Albert Chenevier University Hospital. Blood samples will be collected to assess the association of these biomarkers with HBsAg seroconversion and clinical events like cirrhosis and hepatocellular carcinoma (HCC).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years old
* Chronic HBV infection (HbsAg positive carrier for more than 6 months)
* Patient under care within the Henri Mondor-Albert Chenevier University Hospital group

Exclusion Criteria:

* History of liver transplantation for liver failure in the context of chronic HBV infection
* Protected adults, adults unable to express their consent
* Pregnant or breastfeeding women
* Person not affiliated with a Social Security system
* Patient refusal to participate in the project

Where it's running

• Clinical Research Unit (CRU) Henri Mondor.
  Créteil, Créteil, France Recruiting

Study contacts

• Study coordinator: Vincent LEROY, Dr
• Email: vincent.leroy2@aphp.fr
• Phone: +33 0149812325

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-invasive approach to assess liver fibrosis in chronic hepatitis B patients

  This study is testing a new way to see if liver stiffness measurements can help predict if liver damage improves in people with chronic hepatitis B who have been treated with antiviral therapy.

  Recruiting Beijing Friendship Hospital · Beijing · NCT06874127

• Evaluating a new combination therapy for chronic Hepatitis B infection

  This study is testing a new combination treatment for adults with chronic Hepatitis B who are already on medication to see if it works better than the standard treatment alone.

  Recruiting at 14 sites Phase 2 Brii Biosciences Limited · Beijing, Beijing Municipality and 13 other locations · NCT06650852

• Diffusion MRI to map nerve lesions in obstetric brachial plexus palsy

  This study tests diffusion MRI and tractography to better understand nerve injuries in people with obstetric brachial plexus palsy.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07767708

• Long-term心理 and cognitive check after stem cell transplant for immune deficiencies

  This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07766304

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Gut microbes and autoinflammatory diseases: how they may be linked

  This study tests whether gut bacteria and their byproducts relate to digestive and inflammatory symptoms in people with autoinflammatory diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07718555

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.